Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SEC probes Bayer deal as Trius raises $45.2M to advance tedizolid

This article was originally published in Scrip

Executive Summary

Trius Therapeutics is to raise $45.2 million through the sale of 8.6 million shares at $5.25 per share at a 9.3% discount to the company’s trading price of $5.79 on 25 January. The firm is advancing its lead antibiotic which is in Phase III trials, TR701-112 (tedizolid phosphate), for patients with acute bacterial skin and skin structure infections (ABSSSI).

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC016076

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel